Scholar Rock Reports $102.2 Million Net Loss in Q3 2025, Operating Expenses Surge

Scholar Rock Holding Corporation reported its financial results for the third quarter of 2025, revealing a net loss of $102.2 million, or $0.90 per share, compared to a net loss of $64.5 million, or $0.66 per share, in the same period last year. Total operating expenses surged to $103.6 million, a 59.8% increase from $64.8 million in the prior year, driven primarily by a significant rise in general and administrative expenses, which rose to $53.1 million from $16.1 million. Research and development expenses also increased slightly to $50.5 million from $48.7 million, reflecting ongoing investments in clinical trials and product development.

For the nine months ending September 30, 2025, the company reported a net loss of $287.0 million, compared to a loss of $179.8 million for the same period in 2024. Total operating expenses for the nine-month period reached $292.7 million, up 60.2% from $182.7 million in the previous year. The increase in expenses was attributed to heightened research and development activities, particularly related to the development of its lead product candidate, apitegromab, and the expansion of its workforce to support commercialization efforts.

In terms of liquidity, Scholar Rock's cash and cash equivalents increased to $286.8 million as of September 30, 2025, up from $177.9 million at the end of 2024. However, marketable securities decreased significantly to $82.9 million from $259.4 million. The company generated $155.1 million in net cash from financing activities during the nine months, primarily from the sale of common shares under its at-the-market program, which contributed $91.7 million, and $50 million from its debt facility.

Strategically, Scholar Rock continues to advance its clinical programs, including the pivotal Phase 3 trial of apitegromab for spinal muscular atrophy (SMA), which received a Complete Response Letter from the FDA in September 2025 due to site-related observations at a third-party facility. The company plans to resubmit its Biologics License Application once the facility is reclassified. Additionally, the company is expanding its anti-myostatin program with SRK-439, which has received FDA clearance for an investigational new drug application and is set to begin dosing in healthy volunteers in late 2025.

Looking ahead, Scholar Rock anticipates continued significant operating losses as it invests in the development of its product candidates and prepares for potential commercialization. The company expects its existing cash and marketable securities will fund operations into 2027, but acknowledges the need for additional capital to support ongoing clinical trials and commercialization efforts.